Journals
Publish with us
Publishing partnerships
About us
Blog
Sarcoma
Journal overview
For authors
For reviewers
For editors
Table of Contents
Special Issues
Sarcoma
/
2017
/
Article
/
Tab 1
/
Clinical Study
SARC006: Phase II Trial of Chemotherapy in Sporadic and Neurofibromatosis Type 1 Associated Chemotherapy-Naive Malignant Peripheral Nerve Sheath Tumors
Table 1
Patient characteristics at enrollment and response evaluation.
Stratum
NF1 MPNST
Sporadic MPNST
Eligible patients enrolled
34
14
Male/female
22/12
9/5
Median age: years (range)
33 (8–66)
40 (13–72)
Race:
(%)
White, non-Hispanic
14 (41%)
11 (79%)
Black
13 (38%)
2 (14%)
Hispanic
4 (12%)
0 (0%)
Other/unknown
3 (9%)
1 (7%)
ECOG score: 0/1/2
4/24/6
6/5/3
Disease: localized/metastatic
18/16
5/9
Location
Head
2
0
Neck
3
1
Chest
10
4
Abdomen/pelvis
9
5
Spine
5
1
Upper extremity
3
1
Lower extremity
2
2
Response evaluation after cycle 4
28
9
Complete response (CR)
—
—
Partial response (PR)
5
4
Stable disease (SD)
20
4
Progressive disease (PD)
3
1
Objective response rate: %
17.9
44.4